Novel & Significant Applications With Second Half 2011 User Fee Goals
This article was originally published in Pharmaceutical Approvals Monthly
You may also be interested in...
FDA Sets A Fast Pace Of Novel Approvals In First Half, But That's Likely To Slow
A sparsely populated user fee calendar for the remainder of 2011 likely precludes a repeat of FDA’s stunning approval performance in the first half of this year. Still, with 20 approvals of new molecular entities and novel biologics during those first six months, the agency is all but assured of one of its best years in a decade – at the least.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.